Simon Chell

645 total citations
8 papers, 531 citations indexed

About

Simon Chell is a scholar working on Pharmacology, Genetics and Oncology. According to data from OpenAlex, Simon Chell has authored 8 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pharmacology, 5 papers in Genetics and 3 papers in Oncology. Recurrent topics in Simon Chell's work include Inflammatory mediators and NSAID effects (5 papers), Estrogen and related hormone effects (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). Simon Chell is often cited by papers focused on Inflammatory mediators and NSAID effects (5 papers), Estrogen and related hormone effects (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). Simon Chell collaborates with scholars based in United Kingdom, Australia and United States. Simon Chell's co-authors include Christos Paraskeva, Ann C. Williams, David Qualtrough, Simon J. Cook, Kathryn Balmanno, Shaista Hayat, Andrew Herman, Ian R. Witherden, Abderrahmane Kaidi and Henry N. Jabbour and has published in prestigious journals such as Cancer Research, Oncogene and International Journal of Cancer.

In The Last Decade

Simon Chell

7 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Chell United Kingdom	7	244	216	145	110	100	8	531
Jae Won Soh United States	12	437 1.8×	129 0.6×	258 1.8×	89 0.8×	87 0.9×	12	749
P.‐J. Jakobsson Sweden	8	189 0.8×	401 1.9×	111 0.8×	222 2.0×	150 1.5×	17	665
Sung Hyeok Hong United States	10	324 1.3×	218 1.0×	272 1.9×	131 1.2×	174 1.7×	17	860
Vasan Yegnasubramanian United States	2	279 1.1×	186 0.9×	91 0.6×	85 0.8×	63 0.6×	3	515
Valentina Fabbroni Italy	9	153 0.6×	133 0.6×	55 0.4×	55 0.5×	76 0.8×	12	476
Rut Porta Spain	9	289 1.2×	121 0.6×	114 0.8×	50 0.5×	163 1.6×	17	527
P Yue United States	9	521 2.1×	69 0.3×	178 1.2×	70 0.6×	117 1.2×	15	770
Yande Guo United States	8	249 1.0×	159 0.7×	71 0.5×	71 0.6×	121 1.2×	12	536
Sang‐Hyeok Woo South Korea	17	596 2.4×	75 0.3×	138 1.0×	52 0.5×	159 1.6×	21	847
Sharada Katkuri United States	7	592 2.4×	490 2.3×	212 1.5×	185 1.7×	364 3.6×	7	1.0k

Countries citing papers authored by Simon Chell

Since Specialization

Citations

This map shows the geographic impact of Simon Chell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Chell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Chell more than expected).

Fields of papers citing papers by Simon Chell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Chell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Chell. The network helps show where Simon Chell may publish in the future.

Co-authorship network of co-authors of Simon Chell

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Chell. A scholar is included among the top collaborators of Simon Chell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Chell. Simon Chell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Jones, Nicole M., et al.. (2022). The prolyl hydroxylase inhibitor GSK1120360A reduces early brain injury, but protection is not maintained in a neonatal rat model of hypoxic ischaemic encephalopathy. International Journal of Developmental Neuroscience. 82(5). 423–435.

Balmanno, Kathryn, et al.. (2009). Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. International Journal of Cancer. 125(10). 2332–2341. 115 indexed citations

Wickenden, Julie A., Mark Johnson, Mark Austin, et al.. (2008). Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. Oncogene. 27(57). 7150–7161. 59 indexed citations

Buda, Andrea, Simon Chell, Douglas J.E. Elder, et al.. (2007). Inhibition of COX‐2 with NS‐398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy. Cell Proliferation. 40(5). 768–779. 32 indexed citations

Qualtrough, David, Abderrahmane Kaidi, Simon Chell, et al.. (2007). Prostaglandin F₂_α stimulates motility and invasion in colorectal tumor cells. International Journal of Cancer. 121(4). 734–740. 61 indexed citations

Chell, Simon, Ian R. Witherden, Andrew Herman, et al.. (2006). Increased EP4 Receptor Expression in Colorectal Cancer Progression Promotes Cell Growth and Anchorage Independence. Cancer Research. 66(6). 3106–3113. 126 indexed citations

Chell, Simon, et al.. (2006). Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1766(1). 104–119. 118 indexed citations

Chell, Simon, David Qualtrough, Daniel Hicks, et al.. (2005). Prospects in NSAID-derived chemoprevention of colorectal cancer. Biochemical Society Transactions. 33(4). 667–671. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact